open access

Vol 11, No 5 (2016)
Review paper
Published online: 2016-11-22
Get Citation

Chronic thromboembolic pulmonary hypertension — diagnosis and novel therapeutic options according to ESC/ERS 2015 guidelines

Remigiusz Kazimierczyk, Karol Adam Kamiński
DOI: 10.5603/FC.2016.0094
·
Folia Cardiologica 2016;11(5):394-400.

open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-11-22

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious disease, usually caused by an incomplete recanalization of pulmonary vessels after acute pulmonary embolism. This leads to a significant remodeling of the remaining pulmonary vasculature and right ventricular failure. The prognosis depends on early diagnosis and proper treatment. Despite the availability of an effective method — pulmonary endarterectomy (PEA), more than one-third of patients is not eligible for this type of operation due to the localization and the character of lesions. In these patients, as well as in the persistent CTEPH after PEA, specific therapy with riociguat is recommended. Balloon pulmonary angioplasty, a new treatment method, can be considered in certain patients with inoperable CTEPH.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious disease, usually caused by an incomplete recanalization of pulmonary vessels after acute pulmonary embolism. This leads to a significant remodeling of the remaining pulmonary vasculature and right ventricular failure. The prognosis depends on early diagnosis and proper treatment. Despite the availability of an effective method — pulmonary endarterectomy (PEA), more than one-third of patients is not eligible for this type of operation due to the localization and the character of lesions. In these patients, as well as in the persistent CTEPH after PEA, specific therapy with riociguat is recommended. Balloon pulmonary angioplasty, a new treatment method, can be considered in certain patients with inoperable CTEPH.

Get Citation

Keywords

chronic thromboembolic pulmonary hypertension (CTEPH), right ventricular failure, pulmonary endarterectomy, balloon pulmonary angioplasty, riociguat

About this article
Title

Chronic thromboembolic pulmonary hypertension — diagnosis and novel therapeutic options according to ESC/ERS 2015 guidelines

Journal

Folia Cardiologica

Issue

Vol 11, No 5 (2016)

Article type

Review paper

Pages

394-400

Published online

2016-11-22

DOI

10.5603/FC.2016.0094

Bibliographic record

Folia Cardiologica 2016;11(5):394-400.

Keywords

chronic thromboembolic pulmonary hypertension (CTEPH)
right ventricular failure
pulmonary endarterectomy
balloon pulmonary angioplasty
riociguat

Authors

Remigiusz Kazimierczyk
Karol Adam Kamiński

References (32)
  1. Galiè N, Humbert M, Vachiery JL, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal. 2015; 37(1): 67–119.
  2. Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013; 41(2): 462–468.
  3. Mercier O, Arthur Ataam J, Langer NB, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004; 23(4): 637–648.
  4. Jasiewicz M, Kamiński K. Rozwój nadciśnienia płucnego w przebiegu chorób lewej części serca oraz zmian zakrzepowo-zatorowych. Kardiol. Oparta na Faktach. 2010; 2: 182–188.
  5. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006; 3(7): 564–567.
  6. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001; 345(20): 1465–1472.
  7. Pengo V, Lensing AWA, Prins MH, et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350(22): 2257–2264.
  8. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J. 2000; 15(3): 440–448.
  9. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011; 124(18): 1973–1981.
  10. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993; 103(3): 685–692.
  11. Galiè N, Kim NHS. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7): 571–576.
  12. Klok FA, Dzikowska-Diduch O, Kostrubiec M, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016; 14(1): 121–128.
  13. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation. 2006; 113(16): 2011–2020.
  14. Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982; 81(2): 151–158.
  15. Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7): 568–570.
  16. Yang S, Yang Y, Zhai Z, et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis. 2015; 7(11): 1927–1938.
  17. Moser KM, Braunwald NS. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest. 1973; 64(1): 29–35.
  18. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011; 141(3): 702–710.
  19. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003; 76(5): 1457–1462.
  20. Delcroix M, Lang I, Pepke-Zaba J, et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016; 133(9): 859–871.
  21. Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28(1): 138–143.
  22. Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2007; 5(3): 483–489.
  23. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007; 30(5): 922–927.
  24. Simonneau G, D'Armini AM, Ghofrani HA, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4): 319–329.
  25. Jaïs X, D'Armini AM, Jansa P, et al. Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25): 2127–2134.
  26. Adempas (riociguat). Charakterystyka produktu leczniczego. http://ec.europa.eu/health/documents/community-register/2014/20140327128191/anx_128191_pl.pdf (08.06.2016).
  27. Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015; 45(5): 1293–1302.
  28. Galiè N, Grimminger F, Grünig E, et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4): 330–340.
  29. Rubin L, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): a long-term extension study (PATENT-2). Eur Repsir J. 2015; 45: 26–31.
  30. Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001; 103(1): 10–13.
  31. Kurzyna M, Darocha S, Koteja A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Post Kardiol Interw. 2015; 11: 1–4.
  32. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest. 2001; 119(3): 818–823.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl